• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Edwards Lifesciences Reports First Quarter Results

    4/23/25 4:15:00 PM ET
    $EW
    Industrial Specialties
    Health Care
    Get the next $EW alert in real time by email

    Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended Mar. 31, 2025.

    Recent Highlights

    • Q1 sales grew 6.2% to $1.41 billion, or 7.9% adjusted1
    • Q1 TAVR sales grew 3.8%; constant currency1 sales grew 5.4%, better than expected
    • Q1 TMTT sales grew 58% to $115 million with meaningful contribution to Edwards' growth
    • Q1 EPS of $0.622; adjusted1 EPS of $0.64
    • SAPIEN M3 CE Mark approval uniquely positions Edwards with a comprehensive TMTT portfolio
    • NCD finalized for transcatheter tricuspid valve replacement, expanding patient access to EVOQUE
    • Multiple TAVR studies presented at ACC confirm the need for urgent patient referral to Heart Team
    • Data from Heart Valve Society meeting confirm long-term durability of Edwards' RESILIA tissue

    2025 Outlook

    • Raising TMTT sales guidance range to $530 million to $550 million
    • Reiterating TAVR and Surgical sales growth guidance
    • Reiterating 8-10% Edwards sales growth guidance; increasing sales guidance to $5.7 to $6.1 billion
    • Reaffirming adjusted EPS of $2.40 to $2.50, including estimated JenaValve dilution and tariff impact

    "The many milestones achieved this quarter are the result of our structural heart-focused strategy and our decades of unwavering dedication to driving breakthrough innovation in pioneering and leading categories. Collectively, these milestones mark the significant progress we have made to unlock this large and growing opportunity to transform care for millions of structural heart patients around the world," said Bernard Zovighian, CEO. "We are pleased with our strong start to the year and have confidence in our 2025 outlook. Looking to the future, we will build on the many impactful catalysts for our company, which position us for distinguished growth in the years ahead."

    Transcatheter Aortic Valve Replacement (TAVR)

    In the first quarter, the company reported TAVR sales of $1.05 billion, which grew 3.8% versus the prior year, 5.4% on a constant currency basis, or 6.5% further adjusted for one less billing day. Constant currency growth was comparable in the United States ("U.S.") and Outside of the United States ("OUS"). Edwards' strong competitive position and pricing remained stable globally, with some regional variability.

    In the U.S., the company's leading SAPIEN 3 Ultra RESILIA platform continues to demonstrate strong performance. Edwards is advancing initiatives to help hospitals treat structural heart patients efficiently and manage increasing procedure volumes. The company remains encouraged by hospitals that have demonstrated the ability to scale to accommodate procedure growth. Edwards is encouraged by discussions with key clinicians on the long-term impact of the EARLY TAVR data to streamline patient care. In addition, Edwards expects asymptomatic indication approval in the second quarter.

    Outside of the U.S., the company continues to focus on the value of its differentiated technology and increasing therapy adoption, especially in areas where TAVR remains underutilized and many patients go without care. In the first quarter, sales growth in Europe was supported by the continued expansion of SAPIEN 3 Ultra RESILIA. In Japan, Edwards remains dedicated to addressing the significant undertreatment of aortic stenosis among the substantial elderly population in Japan.

    Transcatheter Mitral and Tricuspid Therapies (TMTT)

    Edwards' unique and increasingly differentiated TMTT portfolio drove another quarter of impressive growth, with a meaningful contribution to overall company performance. First quarter sales were $115 million, representing growth of 58% year-over-year, or more than 60% on a constant currency basis, led by increased adoption and balanced contribution from PASCAL and EVOQUE in the U.S., Europe and globally.

    PASCAL continues to demonstrate its value for patient care. Its differentiated features are driving distinguished clinical outcomes, and adoption is increasing at both new and existing sites around the world. The EVOQUE commercial launch is progressing well in the U.S. and Europe, with continuing excellent patient outcomes. The recent CE Mark approval of the SAPIEN M3 in Europe, the world's first transcatheter mitral valve replacement system, will benefit many patients with mitral regurgitation who have limited treatment options.

    With EVOQUE, SAPIEN M3 and PASCAL, Edwards is uniquely positioned to meet the broad and diverse needs of patients with tricuspid and mitral valve diseases.

    Surgical

    In Surgical, first quarter global sales of $251 million increased 1% over the prior year, or 3% on a constant currency basis. The company continues to see positive procedure growth globally for the many patients best treated with Edwards' premium RESILIA tissue portfolio including MITRIS, INSPIRIS and KONECT.

    Also in the first quarter, Edwards made progress advancing important innovations around the world. MITRIS launched in China with positive surgeon feedback. Additionally, the company anticipates receiving CE Mark approval for the KONECT aortic valved conduit in Europe before year-end.

    Additional Financial Results

    For the quarter, the gross profit margin was 78.7% compared to 78.4% in the same period last year.

    Selling, general and administrative expenses in the first quarter were $466 million, or 33.0% of sales, which was better than the company's expectation for the quarter driven by lower sequential spending and deferral of certain strategic investments originally planned for Q1.

    Research and development expense of $255 million in the quarter was equivalent to 18.0% of sales, a reduction from 19.6% of sales in the previous quarter. This lower ratio of spending reflects the company's prioritized investments in its structural heart portfolio in areas where Edwards believes there are significant opportunities for profitable growth.

    Operating profit margin in the first quarter of 27.9%, or 29.1% adjusted, was driven by better-than-expected sales and favorable mix, as well as some variable expenses delayed beyond Q1.

    Cash and cash equivalents were approximately $3.1 billion as of March 31, 2025. Total debt was approximately $600 million.

    Outlook

    Edwards is raising its 2025 TMTT sales guidance range to $530 to $550 million, from $500 million to $530 million, driven by more favorable foreign exchange and continued business momentum. Separately, total company, TAVR and Surgical sales growth guidance ranges remain unchanged, but the company is increasing its original total company sales dollar guidance range by $100 million to account for recent movement in FX rates. Edwards now expects total company sales of $5.7 to $6.1 billion in 2025. The company expects pressure on its operating margin as a result of the weakening dollar, the impact of announced tariffs and the expected close of the JenaValve acquisition. However, the company is implementing plans to mitigate these anticipated costs and maintains its full-year operating margin guidance of 27% to 28% and EPS guidance of $2.40 to $2.50. For the second quarter of 2025, the company projects total sales to be between $1.45 and $1.53 billion and adjusted EPS of $0.59 to $0.65.

    About Edwards Lifesciences

    Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Discover more at www.edwards.com and follow us on LinkedIn, Facebook, Instagram and YouTube.

    Conference Call and Webcast Information

    The company will be hosting a conference call today at 2:00 p.m. PT to discuss its first quarter results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com or www.edwards.com.

    This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements can sometimes be identified by the use of words such as "may," "will," "should," "anticipate," "believe," "plan," "project," "estimate," "forecast," "potential," "predict," "early clinician feedback," "expect," "intend," "guidance," "outlook," "optimistic," "aspire," "confident" or other forms of these words or similar expressions and include, but are not limited to, statements made by Mr. Zovighian, second quarter and fiscal year 2025 financial guidance, our expected growth and accelerating growth due to, among other things, asymptomatic TAVR approval; durability of our RESILIA tissue; global adoption of, and differentiated features of, our devices; scaling of hospitals to accommodate procedure growth; expansion of evidence, approvals, clinical trial outcomes and impacts; patient outcomes; expectations for R&D and SG&A spending; effects of the JenaValve transaction; the highlights in the Guidance and Outlook section and the information in the Outlook section. No inferences or assumptions should be made from statements of past performance, efforts, or results which may not be indicative of future performance or results. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain, difficult to predict, and may be outside of the company's control. The company's forward-looking statements speak only as of the date on which they are made and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. If the company does update or correct one or more of these statements, investors and others should not conclude that the company will make additional updates or corrections.

    Edwards' guidance reflects the Company's current estimates of the impact from tariffs that are in effect or have been announced as of the time of this press release and assumes such tariffs remain in place for the remainder of 2025. Any modification to such tariffs, or any new tariffs, could have a material impact on the Company's future financial results and guidance.

    Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Factors that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements include risk and uncertainties associated with the risks detailed in the company's filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2024, and its other filings with the SEC. These filings, along with important safety information about our products, may be found at edwards.com.

    Edwards, Edwards Lifesciences, the stylized E logo, EARLY TAVR, EVOQUE, INSPIRIS, KONECT, MITRIS, PARTNER, PARTNER 3, PASCAL, RESILIA, SAPIEN, SAPIEN M3, SAPIEN 3, and SAPIEN 3 Ultra are trademarks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.

    __________________

    [1]

    The company uses the terms "adjusted" and "constant currency" when referring to non-GAAP sales from continuing operations and sales growth information, respectively, which excludes currency rate fluctuations and newly acquired products. Adjusted earnings per share from continuing operations is a non-GAAP item computed on a diluted basis and in this press release also excludes certain litigation expenses, amortization of intangible assets, and separation costs. See "Non-GAAP Financial Information" and reconciliation tables below.

    [2]

    Reported sales and diluted EPS are from continuing operations.

    EDWARDS LIFESCIENCES CORPORATION

    Unaudited Consolidated Statements of Operations

    (in millions, except per share data)

     

     

    Three Months Ended

    March 31,

     

    2025

     

    2024

    Net sales

    $

    1,412.7

     

     

    $

    1,329.9

     

    Cost of sales

     

    301.6

     

     

     

    286.9

     

    Gross profit

     

    1,111.1

     

     

     

    1,043.0

     

    Selling, general, and administrative expenses

     

    465.7

     

     

     

    428.4

     

    Research and development expenses

     

    254.6

     

     

     

    256.7

     

    Intellectual property agreement and certain litigation expenses

     

    10.9

     

     

     

    8.9

     

    Separation costs

     

    4.2

     

     

     

    —

     

    Other operating income, net

     

    (19.1

    )

     

     

    —

     

    Operating income, net

     

    394.8

     

     

     

    349.0

     

    Interest income, net

     

    (36.5

    )

     

     

    (16.5

    )

    Other non-operating income, net

     

    (2.6

    )

     

     

    (5.7

    )

    Income from continuing operations before provision for income taxes

     

    433.9

     

     

     

    371.2

     

    Provision for income taxes

     

    70.3

     

     

     

    46.3

     

    Net income from continuing operations

    $

    363.6

     

     

    $

    324.9

     

    (Loss) income from discontinued operations, net of tax

     

    (7.2

    )

     

     

    26.1

     

    Net income

     

    356.4

     

     

     

    351.0

     

    Net loss attributable to noncontrolling interest

     

    (1.6

    )

     

     

    (0.9

    )

    Net income attributable to Edwards Lifesciences Corporation

    $

    358.0

     

     

    $

    351.9

     

     

     

     

     

    Earnings (loss) per share:

     

     

     

    Basic:

     

     

     

    Continuing operations

    $

    0.62

     

     

    $

    0.54

     

    Discontinued operations

    $

    (0.01

    )

     

    $

    0.04

     

    Basic earnings per share

    $

    0.61

     

     

    $

    0.58

     

    Diluted:

     

     

     

    Continuing operations

    $

    0.62

     

     

    $

    0.54

     

    Discontinued operations

    $

    (0.01

    )

     

    $

    0.04

     

    Diluted earnings per share

    $

    0.61

     

     

    $

    0.58

     

     

     

     

     

    Weighted-average common shares outstanding:

     

     

     

    Basic

     

    586.9

     

     

     

    601.6

     

    Diluted

     

    587.8

     

     

     

    604.1

     

     

     

     

     

    Operating statistics from continuing operations

     

     

     

    As a percentage of net sales:

     

     

     

    Gross profit

     

    78.7

    %

     

     

    78.4

    %

    Selling, general, and administrative expenses

     

    33.0

    %

     

     

    32.2

    %

    Research and development expenses

     

    18.0

    %

     

     

    19.3

    %

    Operating income

     

    27.9

    %

     

     

    26.2

    %

    Income before provision for income taxes

     

    30.7

    %

     

     

    27.9

    %

    Net income from continuing operations

     

    25.7

    %

     

     

    24.4

    %

     

     

     

     

    Effective tax rate

     

    16.2

    %

     

     

    12.5

    %

    ____________________

    Note: Numbers may not calculate due to rounding.

    EDWARDS LIFESCIENCES CORPORATION

    Non-GAAP Financial Information

    To supplement the consolidated financial results prepared in accordance with Generally Accepted Accounting Principles ("GAAP"), the Company uses non-GAAP historical financial measures. Management makes adjustments to the GAAP measures for items (both charges and gains) that (a) do not reflect the core operational activities of the Company, (b) are commonly adjusted within the Company's industry to enhance comparability of the Company's financial results with those of its peer group, or (c) are inconsistent in amount or frequency between periods (albeit such items are monitored and controlled with equal diligence relative to core operations). The Company uses the terms "adjusted" and "constant currency" when referring to non-GAAP sales from continuing operations and sales growth information, respectively, which excludes currency exchange rate fluctuations and newly acquired products. The Company uses the term "adjusted" to also exclude certain litigation expenses, amortization of intangible assets, and separation costs.

    Management uses non-GAAP financial measures internally for strategic decision making, forecasting future results, and evaluating current performance. These non-GAAP financial measures are used in addition to, and in conjunction with, results presented in accordance with GAAP and reflect an additional way of viewing aspects of the Company's operations by investors that, when viewed with its GAAP results, provide a more complete understanding of factors and trends affecting the Company's business and facilitate comparability to historical periods.

    Non-GAAP financial measures are not prepared in accordance with GAAP; therefore, the information is not necessarily comparable to other companies and should be considered as a supplement to, and not as a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. A reconciliation of non-GAAP historical financial measures to the most comparable GAAP measure is provided in the tables below.

    Fluctuations in currency exchange rates impact the comparative results and sales growth rates of the Company's underlying business. Management believes that excluding the impact of currency exchange rate fluctuations from its sales growth provides investors a more useful comparison to historical financial results. The impact of the fluctuations has been detailed in the "Reconciliation of Sales by Product Group and Region."

    Guidance for sales and sales growth rates is provided on a "constant currency basis," and projections for diluted earnings per share, net income and growth, gross profit margin, taxes, and free cash flow are also provided on a non-GAAP basis, as adjusted, for the items identified above due to the inherent difficulty in forecasting such items without unreasonable efforts. The Company is not able to provide a reconciliation of the non-GAAP guidance to comparable GAAP measures due to the unknown effect, timing, and potential significance of special charges or gains, and management's inability to forecast charges associated with future transactions and initiatives.

    Management considers free cash flow to be a liquidity measure which provides useful information to management and investors about the amount of cash generated by business operations, after deducting payments for capital expenditures, which can then be used for strategic opportunities or other business purposes including, among others, investing in the Company's business, making strategic acquisitions, strengthening the balance sheet, and repurchasing stock.

    The items described below are adjustments to the GAAP financial results in the reconciliations that follow:

    Certain Litigation Expenses - The Company incurred certain litigation expenses of $10.9 million and $8.9 million in the first quarter of 2025 and 2024, respectively.

    Amortization of Intangible Assets - The Company recorded amortization expense related to developed technology and patents in the amount of $1.4 million and $0.5 million in the first quarter of 2025 and 2024, respectively.

    Separation Costs - The Company recorded expenses of $4.2 million in the first quarter of 2025 related to consulting, legal, tax, and other professional advisory services related to the sale of Critical Care.

    Provision for Income Taxes - The income tax impacts of the expenses and gains discussed above are based upon the items' forecasted effect upon the Company's full year effective tax rate. Adjustments to forecasted items unrelated to the expenses and gains above, as well as impacts related to interim reporting, will have an effect on the income tax impact of these items in subsequent periods.

    EDWARDS LIFESCIENCES CORPORATION

    Unaudited Reconciliation of GAAP to Non-GAAP Financial Information

    (in millions, except per share and percentage data)

     

     

    Three Months Ended March 31, 2025

     

     

    Net Sales

     

    Gross Profit Margin

     

    Operating Income, net

     

    Operating Profit Margin

     

    Net Income

     

    Diluted EPS

     

    Effective Tax Rate

    GAAP - Continuing Operations

     

    $

    1,412.7

     

    78.7

    %

     

    $

    394.8

     

    27.9

    %

     

    $

    363.6

     

    $

    0.62

     

    16.2

    %

    Net loss attributable to noncontrolling interests

     

     

    —

     

    —

     

     

     

    —

     

    —

     

     

     

    1.6

     

     

    —

     

    —

     

    Total attributable to Edwards Lifesciences Corporation

     

     

    1,412.7

     

    78.7

    %

     

     

    394.8

     

    27.9

    %

     

     

    365.2

     

     

    0.62

     

    16.2

    %

    Non-GAAP adjustments: (A) (B)

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Certain litigation expenses

     

     

    —

     

    —

     

     

     

    10.9

     

    0.8

     

     

     

    8.8

     

     

    0.01

     

    0.1

     

    Amortization of intangible assets

     

     

    —

     

    —

     

     

     

    1.4

     

    0.1

     

     

     

    1.2

     

     

    —

     

    —

     

    Separation costs

     

     

    —

     

    —

     

     

     

    4.2

     

    0.3

     

     

     

    3.4

     

     

    0.01

     

    —

     

    Adjusted

     

    $

    1,412.7

     

    78.7

    %

     

    $

    411.3

     

    29.1

    %

     

    $

    378.6

     

    $

    0.64

     

    16.3

    %

     

     

    Three Months Ended March 31, 2024

     

     

    Net Sales

     

    Gross Profit Margin

     

    Operating Income, net

     

    Operating Profit Margin

     

    Net Income

     

    Diluted EPS

     

    Effective Tax Rate

    GAAP - Continuing Operations

     

    $

    1,329.9

     

    78.4

    %

     

    $

    349.0

     

    26.2

    %

     

    $

    324.9

     

    $

    0.54

     

    12.5

    %

    Net loss attributable to noncontrolling interests

     

     

    —

     

    —

     

     

     

    —

     

    —

     

     

     

    0.9

     

     

    —

     

    —

     

    Total attributable to Edwards Lifesciences Corporation

     

     

    1,329.9

     

    78.4

    %

     

     

    349.0

     

    26.2

    %

     

     

    325.8

     

     

    0.54

     

    12.5

    %

    Non-GAAP adjustments: (A) (B)

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Certain litigation expenses

     

     

    —

     

    —

     

     

     

    8.9

     

    0.7

     

     

     

    7.4

     

     

    0.01

     

    0.1

     

    Amortization of intangible assets

     

     

    —

     

    0.1

     

     

     

    0.5

     

    —

     

     

     

    0.4

     

     

    —

     

    —

     

    Adjusted

     

    $

    1,329.9

     

    78.5

    %

     

    $

    358.4

     

    26.9

    %

     

    $

    333.6

     

    $

    0.55

     

    12.6

    %

    ____________________
    (A)

    See description of non-GAAP adjustments under "Non-GAAP Financial Information."

    (B)

    The tax effect on non-GAAP adjustments is calculated based upon the impact of the relevant tax jurisdictions' statutory tax rates on the Company's estimated annual effective tax rate, or discrete rate in the quarter, as applicable. The impact on the effective tax rate is reflected on each individual non-GAAP adjustment line item.

    RECONCILIATION OF SALES BY PRODUCT GROUP AND REGION

     

     

     

     

     

     

     

     

     

     

    2025 Adjusted

     

    2024 Adjusted

     

     

    Sales by Product Group (QTD) - Continuing Operations

     

    1Q 2025

     

    1Q 2024

     

    Change

     

    GAAP

    Growth

    Rate*

     

    Implantable Heart Failure Management

     

    1Q 2025 Adjusted Sales

     

    FX

    Impact

     

    1Q 2024 Adjusted Sales

     

    Constant Currency

    Growth

    Rate *

    Transcatheter Aortic Valve Replacement

     

    $

    1,046.6

     

    $

    1,007.9

     

    $

    38.7

     

    3.8

    %

     

    $

    —

     

     

    $

    1,046.6

     

    $

    (15.1

    )

     

    $

    992.8

     

    5.4

    %

    Transcatheter Mitral and Tricuspid Therapies

     

     

    115.2

     

     

    72.9

     

     

    42.3

     

    58.1

    %

     

     

    (0.4

    )

     

     

    114.8

     

     

    (1.8

    )

     

     

    71.1

     

    61.4

    %

    Surgical Structural Heart

     

     

    250.9

     

     

    249.1

     

     

    1.8

     

    0.7

    %

     

     

    —

     

     

     

    250.9

     

     

    (4.6

    )

     

     

    244.5

     

    2.6

    %

    Total

     

    $

    1,412.7

     

    $

    1,329.9

     

    $

    82.8

     

    6.2

    %

     

    $

    (0.4

    )

     

    $

    1,412.3

     

    $

    (21.5

    )

     

    $

    1,308.4

     

    7.9

    %

     

     

     

     

     

     

     

     

     

    2025 Adjusted

     

    2024 Adjusted

     

     

    Sales by Region (QTD) - Continuing Operations

     

    1Q 2025

     

    1Q 2024

     

    Change

     

    GAAP

    Growth Rate*

     

    Implantable Heart Failure Management

     

    1Q 2025 Adjusted Sales

     

    FX

    Impact

     

    1Q 2024 Adjusted Sales

     

    Constant Currency

    Growth

    Rate *

    United States

     

    $

    838.9

     

    $

    782.1

     

    $

    56.8

     

     

    7.3

    %

     

    $

    (0.4

    )

     

    $

    838.5

     

    $

    —

     

     

    $

    782.1

     

    7.2

    %

    Europe

     

     

    341.8

     

     

    326.0

     

     

    15.8

     

     

    4.9

    %

     

     

    —

     

     

     

    341.8

     

     

    (11.9

    )

     

     

    314.1

     

    8.8

    %

    Japan

     

     

    81.8

     

     

    86.0

     

     

    (4.2

    )

     

    (4.9

    )%

     

     

    —

     

     

     

    81.8

     

     

    (3.4

    )

     

     

    82.6

     

    (1.0

    )%

    Rest of World

     

     

    150.2

     

     

    135.8

     

     

    14.4

     

     

    10.6

    %

     

     

    —

     

     

     

    150.2

     

     

    (6.2

    )

     

     

    129.6

     

    15.9

    %

    Outside of the United States

     

     

    573.8

     

     

    547.8

     

     

    26.0

     

     

    4.8

    %

     

     

    —

     

     

     

    573.8

     

     

    (21.5

    )

     

     

    526.3

     

    9.0

    %

    Total

     

    $

    1,412.7

     

    $

    1,329.9

     

    $

    82.8

     

     

    6.2

    %

     

    $

    (0.4

    )

     

    $

    1,412.3

     

    $

    (21.5

    )

     

    $

    1,308.4

     

    7.9

    %

    ____________________

    * Numbers may not calculate due to rounding.

     

     

     

     

    Three Months Ended

    March 31,

     

    2025

    TAVR constant currency growth rate

    5.4

    %

    Impact of billing days

    1.1

    %

    TAVR billing days adjusted growth rate

    6.5

    %

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250423533284/en/

    Media Contact: Amy Meshulam, 949-250-4009

    Investor Contact: Mark Wilterding, 949-250-6826

    Get the next $EW alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EW

    DatePrice TargetRatingAnalyst
    4/24/2025$80.00Neutral → Overweight
    Piper Sandler
    1/30/2025$75.00 → $90.00Hold → Buy
    Stifel
    1/16/2025$60.00Peer Perform → Underperform
    Wolfe Research
    12/16/2024Neutral → Buy
    BofA Securities
    10/11/2024$70.00Equal-Weight
    Morgan Stanley
    9/18/2024$85.00 → $70.00Buy → Hold
    Jefferies
    7/31/2024Neutral → Outperform
    Daiwa Securities
    7/29/2024Underperform → Peer Perform
    Wolfe Research
    More analyst ratings

    $EW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Edwards Lifesciences Corporation

      SC 13G - Edwards Lifesciences Corp (0001099800) (Subject)

      11/8/24 10:34:33 AM ET
      $EW
      Industrial Specialties
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Edwards Lifesciences Corporation

      SC 13G/A - Edwards Lifesciences Corp (0001099800) (Subject)

      10/4/24 2:14:28 PM ET
      $EW
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Edwards Lifesciences Corporation (Amendment)

      SC 13G/A - Edwards Lifesciences Corp (0001099800) (Subject)

      2/13/24 5:04:42 PM ET
      $EW
      Industrial Specialties
      Health Care

    $EW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $EW
    Financials

    Live finance-specific insights

    See more

    $EW
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • CVP, TMTT Chopra Daveen sold $112,612 worth of shares (1,500 units at $75.08), decreasing direct ownership by 4% to 33,496 units (SEC Form 4)

      4 - Edwards Lifesciences Corp (0001099800) (Issuer)

      5/22/25 5:08:08 PM ET
      $EW
      Industrial Specialties
      Health Care
    • CEO Zovighian Bernard J gifted 5,816 shares and received a gift of 5,816 shares, decreasing direct ownership by 7% to 80,976 units (SEC Form 4)

      4 - Edwards Lifesciences Corp (0001099800) (Issuer)

      5/16/25 6:22:59 PM ET
      $EW
      Industrial Specialties
      Health Care
    • CEO Zovighian Bernard J covered exercise/tax liability with 2,860 shares, gifted 2,771 shares and received a gift of 2,771 shares, decreasing direct ownership by 6% to 86,792 units (SEC Form 4)

      4 - Edwards Lifesciences Corp (0001099800) (Issuer)

      5/13/25 5:16:17 PM ET
      $EW
      Industrial Specialties
      Health Care
    • Edwards Lifesciences Reports First Quarter Results

      Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended Mar. 31, 2025. Recent Highlights Q1 sales grew 6.2% to $1.41 billion, or 7.9% adjusted1 Q1 TAVR sales grew 3.8%; constant currency1 sales grew 5.4%, better than expected Q1 TMTT sales grew 58% to $115 million with meaningful contribution to Edwards' growth Q1 EPS of $0.622; adjusted1 EPS of $0.64 SAPIEN M3 CE Mark approval uniquely positions Edwards with a comprehensive TMTT portfolio NCD finalized for transcatheter tricuspid valve replacement, expanding patient access to EVOQUE Multiple TAVR studies presented at ACC confirm the need for urgent patient referral to Heart Team Data from Hear

      4/23/25 4:15:00 PM ET
      $EW
      Industrial Specialties
      Health Care
    • Edwards Lifesciences to Host Earnings Conference Call on April 23, 2025

      Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended March 31, 2025 after the market closes on Wednesday April 23, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and

      4/16/25 7:05:00 AM ET
      $EW
      Industrial Specialties
      Health Care
    • Edwards Lifesciences Reports Fourth Quarter Results

      Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter and full-year ended Dec. 31, 2024. Highlights and Outlook Q4 sales grew 9% to $1.39 billion1, better than expected, with strength across all product groups Q4 TAVR sales grew 6%; constant currency2 sales grew 5% Q4 TMTT sales grew 88% to $105 million with increasing contribution to Edwards' growth Q4 EPS of $0.581; adjusted2 EPS of $0.59, driven by strong top-line performance Presented results of two practice-changing FDA clinical trials, EARLY TAVR and TRISCEND II Reiterating 2025 constant currency sales growth of 8% - 10%; adjusted EPS of $2.40 - $2.50 Continuing to expect mid-year asymp

      2/11/25 4:15:00 PM ET
      $EW
      Industrial Specialties
      Health Care
    • Edwards Lifesciences upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Edwards Lifesciences from Neutral to Overweight and set a new price target of $80.00

      4/24/25 7:18:16 AM ET
      $EW
      Industrial Specialties
      Health Care
    • Edwards Lifesciences upgraded by Stifel with a new price target

      Stifel upgraded Edwards Lifesciences from Hold to Buy and set a new price target of $90.00 from $75.00 previously

      1/30/25 7:10:09 AM ET
      $EW
      Industrial Specialties
      Health Care
    • Edwards Lifesciences downgraded by Wolfe Research with a new price target

      Wolfe Research downgraded Edwards Lifesciences from Peer Perform to Underperform and set a new price target of $60.00

      1/16/25 7:43:13 AM ET
      $EW
      Industrial Specialties
      Health Care

    $EW
    SEC Filings

    See more
    • SEC Form SD filed by Edwards Lifesciences Corporation

      SD - Edwards Lifesciences Corp (0001099800) (Filer)

      5/30/25 4:27:10 PM ET
      $EW
      Industrial Specialties
      Health Care
    • Edwards Lifesciences Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Edwards Lifesciences Corp (0001099800) (Filer)

      5/8/25 5:11:37 PM ET
      $EW
      Industrial Specialties
      Health Care
    • SEC Form 10-Q filed by Edwards Lifesciences Corporation

      10-Q - Edwards Lifesciences Corp (0001099800) (Filer)

      5/6/25 4:13:32 PM ET
      $EW
      Industrial Specialties
      Health Care

    $EW
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Prompt Intervention for Severe Aortic Stenosis Patients Demonstrates Lower Healthcare Costs, Improved Clinical Outcomes

      Edwards Lifesciences (NYSE:EW) today announced new economic and clinical evidence on severe aortic stenosis (AS) presented as a late-breaking clinical trial at EuroPCR 2025, further contributing to the extensive body of research on this disease. The results of a new real-world study of more than 24,000 patients demonstrated that intervening on the disease before symptoms develop reduces the economic and resource burden on the healthcare system and improves patient outcomes. Prompt intervention for severe AS patients before symptoms developed resulted in: Significantly lower costs for the healthcare system at 1 year ($36,000 less per patient); Shorter length of stay during their treatm

      5/22/25 2:30:00 AM ET
      $EW
      Industrial Specialties
      Health Care
    • Edwards Lifesciences to Present at the BofA Securities 2025 Health Care Conference

      Edwards Lifesciences (NYSE:EW) today announced it will participate in the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025. Bernard Zovighian, chief executive officer, and Scott Ullem, chief financial officer, will participate in a fireside chat at 10:40 a.m. Pacific Time. A live webcast of the discussion will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com, with an archived version accessible later the same day. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and p

      5/6/25 7:05:00 AM ET
      $EW
      Industrial Specialties
      Health Care
    • Edwards TAVR Receives FDA Approval for Patients With Asymptomatic Severe Aortic Stenosis

      Transforming Care for Severe AS Patients Edwards Lifesciences (NYSE:EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy, the SAPIEN 3 platform, for severe aortic stenosis (AS) patients without symptoms, marking the first FDA approval for TAVR in asymptomatic patients. Approval of the SAPIEN 3 platform (SAPIEN 3, SAPIEN 3 Ultra and SAPIEN 3 Ultra RESILIA) is based on groundbreaking data from the EARLY TAVR trial, which demonstrated that asymptomatic severe AS patients randomized to Edwards TAVR experienced superior outcomes compared to guideline-recommended clinical surveillance (watchful waiting). Wit

      5/1/25 8:00:00 AM ET
      $EW
      Industrial Specialties
      Health Care

    $EW
    Leadership Updates

    Live Leadership Updates

    See more
    • Scaling its Investment Platform in Minimally Invasive Care, Intuitive Ventures Appoints Terri Burke as Senior Partner and Ross Jaffe as Venture Advisor

      Intuitive Ventures today announced the appointment of Terri Burke, former head medtech investments at Epidarex Capital and a seasoned operator, as Senior Partner and Dr. Ross Jaffe, a co-founder of Versant Ventures, as Venture Advisor. Both medtech veterans, they will help support the continued growth of Intuitive Ventures in investing in start-ups reimagining the future of minimally invasive care. With more than two decades of medtech investing and operational leadership experience, Burke will help support the growth of the firm's investment platform. With over $250 million in assets under management, Intuitive Ventures invests in founders tackling large, meaningful problems that positive

      3/6/25 8:00:00 AM ET
      $EW
      Industrial Specialties
      Health Care
    • EDWARDS LIFESCIENCES ANNOUNCES CEO SUCCESSION PLAN

      IRVINE, Calif., Dec. 8, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE:EW) today announced that following regular succession planning discussions with the Board of Directors, Edwards' chairman and CEO, Michael A. Mussallem, who recently turned 70, has informed the Board of his decision to retire as CEO in connection with the company's Annual Meeting of Stockholders on May 11, 2023. At the 2023 annual meeting, Mussallem will stand for election as non-executive chairman of Edwards' Board. He will be succeeded as CEO by Bernard Zovighian, currently corporate vice pre

      12/8/22 8:00:00 AM ET
      $EW
      Industrial Specialties
      Health Care
    • Edwards Announces Updates From Annual Meeting

      IRVINE, Calif., May 5, 2021 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE:EW) today announced updates from its annual meeting, in which Edwards' stockholders voted with the board's recommendations on all proxy proposals: All eight director nominees were elected as directors of the company for a one-year term; Stockholders advised that they approve the compensation of the company's named executive officers; Stockholders have approved the Amendment and Restatement of the company's U.S. and International Employee Stock Purchase Plans; Stockholders have ratified the appoi

      5/5/21 9:15:00 AM ET
      $EW
      Industrial Specialties
      Health Care

    $EW
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Zovighian Bernard J covered exercise/tax liability with 4,245 shares, converted options into 6,265 shares and bought $49,753 worth of shares (580 units at $85.74), increasing direct ownership by 5% to 46,836 units (SEC Form 4)

      4 - Edwards Lifesciences Corp (0001099800) (Issuer)

      5/7/24 5:53:27 PM ET
      $EW
      Industrial Specialties
      Health Care